Home > Result Summaries: Compounds > Combined Measles, Mumps, Rubella, Varicella Vaccine > Result Summary for 208136/017

Result Summary for 208136/017

Result Summary

Protocol ID:	208136/017
Clinical Study ID:	208136/017 (MeMuRu-OKA-017)
Official Title:	Study to assess immunogenicity, reactogenicity and safety of a 2nd dose of GlaxoSmithKline Biologicals’ measles-mumps-rubella-varicella (MeMuRu-OKA) vaccine given in healthy children of 5 to 6 years of age
Phase:	Phase 2
Study Indications or Diseases:	Measles-Mumps-Rubella-Varicella Vaccine
Generic Name:	Combined Measles, Mumps, Rubella, Varicella Vaccine
Trade/Product Name:	Priorix-Tetra;Priorix-Tetra
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Vesikari T et al. (2007) Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella (MMRV) vaccine in healthy children aged 5–6 years. Pediatr Infect Dis J. 26(2):153-158. Knuf M et al. (2008) A combination vaccine against measles, mumps, rubella and varicella. Drugs Today (Barc). 44(4):279-292. Sohita D et al. (2008) Live Attenuated Measles, Mumps, Rubella, and Varicella Zoster Virus Vaccine (Priorix-Tetra). Pediatric Drugs. 10(5): 337-347.